A new approach to tackling autoimmune and inflammatory diseases just got a significant boost. Lycia Therapeutics, a biotech startup focused on extracellular protein degradation, has closed a $180.0M Series A funding round.
The company's novel LYTAC therapeutics are designed to bind and remove disease-causing extracellular proteins by directing them into the cell for degradation via the lysosome. This platform aims to fill critical gaps in targeting proteins outside the cell, promising new options for patients in urgent need.
.png&w=3840&q=75)
